{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:30:07Z","timestamp":1793331007619,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.critrevonc.2019.102837","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T02:21:05Z","timestamp":1574734865000},"page":"102837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":132,"special_numbering":"C","title":["Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2833-6051","authenticated-orcid":false,"given":"Hikmat","family":"Abdel-Razeq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Supplement 3","key":"10.1016\/j.critrevonc.2019.102837_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.13-S3-1","article-title":"Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update","volume":"13","author":"Aapro","year":"2008","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.critrevonc.2019.102837_bib0010","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.surg.2012.06.008","article-title":"Blood transfusion and cancer surgery outcomes: a continued reason for concern","volume":"152","author":"Al-Refaie","year":"2012","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0015","first-page":"CD005033","article-title":"Perioperative blood transfusions and recurrence of colorectal cancer","author":"Amato","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.chom.2014.12.001","article-title":"Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus","volume":"17","author":"Arezes","year":"2015","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102837_bib0025","first-page":"21","article-title":"Intravenous iron for treating cancer-induced anemia: meeting an unmet need?","volume":"1","author":"Auerbach","year":"2012","journal-title":"Chinese Clin Oncol"},{"issue":"7","key":"10.1016\/j.critrevonc.2019.102837_bib0030","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous Iron Optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related Anemia: a multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","article-title":"The safety of intravenous iron preparations","volume":"90","author":"Avni","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.102837_bib0040","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1172\/JCI59770","article-title":"Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy","volume":"122","author":"Baek","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.critrevonc.2019.102837_bib0045","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2006.10.4620","article-title":"Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia","volume":"26","author":"Bastit","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2013.10.008","article-title":"Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis\u2014a critical review","volume":"89","author":"Beguin","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2019.102837_bib0055","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/bjc.2014.171","article-title":"Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data","volume":"111","author":"Bohlius","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2019.102837_bib0065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1185\/03007995.2012.761599","article-title":"Tolerability of different oral iron supplements: a systematic review","volume":"29","author":"Cancelo-Hidalgo","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"issue":"12","key":"10.1016\/j.critrevonc.2019.102837_bib0070","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review","volume":"91","author":"Caro","year":"2001","journal-title":"Cancer"},{"issue":"3 Suppl 7","key":"10.1016\/j.critrevonc.2019.102837_bib0075","first-page":"43","article-title":"Factors influencing quality of life in cancer patients: anemia and fatigue","volume":"25","author":"Cella","year":"1998","journal-title":"Semin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102837_bib0080","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ygyno.2018.08.040","article-title":"Peri-operative allogeneic blood transfusion is associated with poor overall survival in advanced epithelial ovarian cancer; potential impact of patient blood management on cancer outcomes","volume":"151","author":"Connor","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2019.102837_bib0085","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2174\/187152008785914798","article-title":"Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression","volume":"8","author":"Cosse","year":"2008","journal-title":"Anticancer Agents Med. Chem."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.102837_bib0090","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.10763","article-title":"Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy","volume":"95","author":"Crawford","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102837_bib0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7861\/clinmedicine.13-2-193","article-title":"Anaemia of chronic disease","volume":"13","author":"Cullis","year":"2013","journal-title":"Clin Med (Northfield Il)"},{"issue":"Suppl 2","key":"10.1016\/j.critrevonc.2019.102837_bib0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1634\/theoncologist.5-suppl_2-9","article-title":"The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2","volume":"5","author":"Curt","year":"2000","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.critrevonc.2019.102837_bib0105","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ygyno.2009.12.004","article-title":"Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy","volume":"116","author":"Dangsuwan","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102837_bib0110","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1148\/radiology.201.2.8888257","article-title":"Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study","volume":"201","author":"Dubray","year":"1996","journal-title":"Radiology"},{"issue":"11","key":"10.1016\/j.critrevonc.2019.102837_bib0115","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/ndt\/14.11.2595","article-title":"Is there material hazard to treatment with intravenous iron?","volume":"14","author":"Fishbane","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.102837_bib0120","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","article-title":"Clinical evaluation of once-weekly dosing of Epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing","volume":"19","author":"Gabrilove","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/0284186X.2012.702921","article-title":"Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia \u2013 systematic review and meta-analysis of randomised controlled trials","volume":"52","author":"Gafter-Gvili","year":"2013","journal-title":"Acta Oncol (Madr)"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0130","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12885-016-2686-2","article-title":"Is there any role of intravenous iron for the treatment of anemia in cancer?","volume":"16","author":"Gemici","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12185-017-2373-3","article-title":"Modern iron replacement therapy: clinical and pathophysiological insights","volume":"107","author":"Girelli","year":"2018","journal-title":"Int. J. Hematol."},{"issue":"23","key":"10.1016\/j.critrevonc.2019.102837_bib0140","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1182\/blood-2010-05-286260","article-title":"Detection, evaluation, and management of iron-restricted erythropoiesis","volume":"116","author":"Goodnough","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2019.102837_bib0145","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1634\/theoncologist.2007-0241","article-title":"Treating Anemia of cancer with Every-4-Week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study","volume":"13","author":"Gordon","year":"2008","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.critrevonc.2019.102837_bib0150","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1528::AID-CNCR20>3.0.CO;2-E","article-title":"The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix","volume":"86","author":"Grogan","year":"1999","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0155","first-page":"13","article-title":"Safety and efficacy of intravenous administration of iron preparations","volume":"74","author":"Grzywacz","year":"2017","journal-title":"Acta Pol. Pharm."},{"issue":"6","key":"10.1016\/j.critrevonc.2019.102837_bib0160","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/JOP.0863501","article-title":"Continued regulatory actions affecting the use of erythropoiesis-stimulating agents","volume":"4","author":"Hagerty","year":"2008","journal-title":"J. Oncol. Pract."},{"issue":"6","key":"10.1016\/j.critrevonc.2019.102837_bib0165","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.amjsurg.2013.10.001","article-title":"Blood transfusions in colorectal cancer surgery: incidence, outcomes, and predictive factors: an American College of Surgeons National Surgical Quality Improvement Program analysis","volume":"206","author":"Halabi","year":"2013","journal-title":"Am. J. Surg."},{"issue":"Suppl 5(suppl_5)","key":"10.1016\/j.critrevonc.2019.102837_bib0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1634\/theoncologist.9-90005-31","article-title":"Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?","volume":"9","author":"Harrison","year":"2004","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.critrevonc.2019.102837_bib0175","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","article-title":"Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study","volume":"122","author":"Hedenus","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"29","key":"10.1016\/j.critrevonc.2019.102837_bib0180","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2006.06.2737","article-title":"Do erythropoietin receptors on cancer cells explain unexpected clinical findings?","volume":"24","author":"Henke","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"9392","key":"10.1016\/j.critrevonc.2019.102837_bib0185","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.critrevonc.2019.102837_bib0190","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","article-title":"Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects","volume":"93","author":"H\u00f6ckel","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102837_bib0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tmrv.2010.11.001","article-title":"Adverse blood transfusion outcomes: establishing causation","volume":"25","author":"Isbister","year":"2011","journal-title":"Transfus. Med. Rev."},{"issue":"7","key":"10.1016\/j.critrevonc.2019.102837_bib0200","doi-asserted-by":"crossref","first-page":"E133","DOI":"10.1002\/ajh.24013","article-title":"Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation","volume":"90","author":"Jaspers","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"21","key":"10.1016\/j.critrevonc.2019.102837_bib0205","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1001\/archinte.168.21.2377","article-title":"Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer","volume":"168","author":"Khorana","year":"2008","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0210","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2006.11.014","article-title":"Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy","volume":"105","author":"Kim","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2019.102837_bib0215","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast Cancer Receiving first-line chemotherapy: a survival study","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.102837_bib0220","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"2 Suppl 8","key":"10.1016\/j.critrevonc.2019.102837_bib0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0093-7754(01)90206-4","article-title":"Symptomatology of anemia","volume":"28","author":"Ludwig","year":"2001","journal-title":"Semin. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2019.102837_bib0230","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig","year":"2004","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2019.102837_bib0235","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.ejca.2009.02.003","article-title":"Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer treatment (ACT) study","volume":"45","author":"Ludwig","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.102837_bib0240","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3389\/fphys.2018.01294","article-title":"Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach","volume":"9","author":"Madeddu","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.critrevonc.2019.102837_bib0245","first-page":"CD009624","article-title":"The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents","volume":"2","author":"Mhaskar","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0250","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/1471-2407-14-503","article-title":"BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study","volume":"14","author":"Michallet","year":"2014","journal-title":"BMC Cancer"},{"issue":"22","key":"10.1016\/j.critrevonc.2019.102837_bib0255","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1161\/CIRCULATIONAHA.107.698977","article-title":"Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery","volume":"116","author":"Murphy","year":"2007","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.critrevonc.2019.102837_bib0260","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","article-title":"IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin","volume":"113","author":"Nemeth","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"13\u201314","key":"10.1016\/j.critrevonc.2019.102837_bib0265","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10354-016-0508-4","article-title":"Iron, microbiota and colorectal cancer","volume":"166","author":"Ng","year":"2016","journal-title":"Wiener Med. Wochenschr."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.102837_bib0270","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1074\/jbc.M008923200","article-title":"A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during Iron overload","volume":"276","author":"Pigeon","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2019.102837_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2016.03.010","article-title":"How low should we go: a systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology","volume":"46","author":"Prescott","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0280","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2007-08-109488","article-title":"Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology\/American Society of Clinical Oncology clinical practice guideline update","volume":"111","author":"Rizzo","year":"2008","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.critrevonc.2019.102837_bib0285","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2010-08-300541","article-title":"American society of hematology\/American society of clinical oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer","volume":"116","author":"Rizzo","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0290","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2007.14.3396","article-title":"Use of epoetin and Darbepoetin in patients with cancer: 2007 american society of clinical Oncology\/American society of hematology clinical practice guideline update","volume":"26","author":"Rizzo","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.critrevonc.2019.102837_bib0295","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1200\/JCO.2010.29.2201","article-title":"American society of clinical oncology\/American society of hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer","volume":"28","author":"Rizzo","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3_Supplement_2","key":"10.1016\/j.critrevonc.2019.102837_bib0300","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2146\/ajhp060601","article-title":"Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols","volume":"64","author":"Schwartz","year":"2007","journal-title":"Am. J. Health. Syst. Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.102837_bib0305","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1001\/jamaoncol.2017.5179","article-title":"Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix: a randomized clinical trial","volume":"4","author":"Shrivastava","year":"2018","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102837_bib0310","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/annonc\/mds338","article-title":"Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia","volume":"24","author":"Steinmetz","year":"2013","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102837_bib0315","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s10147-013-0544-7","article-title":"Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients","volume":"19","author":"Thomaidis","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102837_bib0320","doi-asserted-by":"crossref","first-page":"e0117383","DOI":"10.1371\/journal.pone.0117383","article-title":"Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. Strnad P, ed","volume":"10","author":"Tolkien","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2019.102837_bib0325","first-page":"CD003407","article-title":"Erythropoietin or darbepoetin for patients with cancer","volume":"12","author":"Tonia","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2019.102837_bib0330","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3495","article-title":"Iron and cancer: more ore to be mined","volume":"13","author":"Torti","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2019.102837_bib0335","first-page":"656","article-title":"Blood product transfusion and cancer prognosis","volume":"7","author":"Upile","year":"2009","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2019.102837_bib0340","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/94.16.1211","article-title":"Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy","volume":"94","author":"Vansteenkiste","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102837_bib0345","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","article-title":"Hypoxia in cancer: significance and impact on clinical outcome","volume":"26","author":"Vaupel","year":"2007","journal-title":"Cancer Metastasis Rev."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102837_bib0350","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00066-006-1543-7","article-title":"Impact of Hemoglobin Levels on Tumor Oxygenation: the Higher, the Better?","volume":"182","author":"Vaupel","year":"2006","journal-title":"Strahlenther. Onkol."},{"issue":"2 Suppl 8","key":"10.1016\/j.critrevonc.2019.102837_bib0355","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0093-7754(01)90210-6","article-title":"Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy","volume":"28","author":"Vaupel","year":"2001","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0360","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.suronc.2017.01.005","article-title":"Long-term prognostic value of preoperative anemia in patients with colorectal cancer: a systematic review and meta-analysis","volume":"26","author":"Wilson","year":"2017","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102837_bib0365","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.mehy.2017.12.011","article-title":"Iron therapy as treatment of anemia: a potentially detrimental and hazardous strategy in colorectal cancer patients","volume":"110","author":"Wilson","year":"2018","journal-title":"Med. Hypotheses"},{"issue":"9","key":"10.1016\/j.critrevonc.2019.102837_bib0370","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","article-title":"Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia","volume":"25","author":"Wright","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2019.102837_bib0375","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","article-title":"Interleukin-6 induces hepcidin expression through STAT3","volume":"108","author":"Wrighting","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102837_bib0380","doi-asserted-by":"crossref","first-page":"12291","DOI":"10.1038\/srep12291","article-title":"Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells","volume":"5","author":"Wu","year":"2015","journal-title":"Sci. Rep."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842819302239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842819302239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:31:27Z","timestamp":1760902287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842819302239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":76,"alternative-id":["S1040842819302239"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102837","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102837"}}